9月9日，汉邦科技(688755.SH)披露公告称，公司与思拓凡(Cytiva)之间的三起专利侵权诉讼取得阶段性 进展。根据招股说明书及临时公告，其中两起涉案专利已被国家知识产权局宣告无效，另一项诉讼仍在 最高人民法院审理中。 公告显示，双方纠纷涉及自动轴向压缩层析柱、自动匀浆罐等相关产品。"色谱柱"专利诉讼中，南京市 中级人民法院一审曾判定汉邦科技侵权，但随后该专利被国家知识产权局宣告无效，最高人民法院终审 裁定撤销原判，驳回思拓凡起诉，该案已结案。"分离介质浆料罐"专利诉讼中，涉案专利亦被宣告无 效。"柱装填方法"专利诉讼中，一审判定汉邦科技不构成侵权，思拓凡不服上诉，目前该案正在最高人 民法院审理，尚无终审结果。 公司表示，作为以色谱技术为核心的高新技术企业，二十余年深耕色谱技术，公司始终以"打造国际色 谱行业第一品牌"为目标，构建起覆盖"色谱柱技术—系统集成—应用解决方案"的全链条创新体系。(齐 和宁) 汉邦科技长期专注色谱技术研发，已形成涵盖色谱柱技术、系统集成及应用解决方案的技术体系，并成 功突破了色谱线性放大等"卡脖子"技术，实现了从克级到千克级分离纯化的技术应用，相关成果已用于 抗体、疫苗、胰 ...

Core Viewpoint - The report outlines the ongoing supervision and assessment of Suzhou Saifen Technology Co., Ltd. by CITIC Securities, focusing on the company's financial performance, core competencies, and potential risks associated with its operations in the chromatography industry. Summary by Sections Continuous Supervision Overview - CITIC Securities conducted a site inspection of the company from August 13 to August 14, 2025, reviewing governance documents, financial management, internal controls, and fundraising management [1]. Issues and Rectification - No significant issues were identified during the supervision period [2]. Major Risk Items - **Core Competitiveness Risk**: The company has developed unique technologies over 20 years, including microsphere synthesis and surface modification. Failure to protect these technologies could weaken its market position [2]. - **Operational Risks**: The company faces challenges in managing its overseas subsidiary, which accounts for 18.20% of its revenue, including risks related to local compliance and currency fluctuations [4]. Financial Performance - The company reported a revenue of 182.63 million yuan in the first half of 2025, a 19.76% increase year-on-year. Net profit attributable to shareholders was 53.66 million yuan, up 40.91% [17]. - The cash flow from operating activities was 35.72 million yuan, reflecting a 36.32% increase due to higher sales [17]. Core Competitiveness - The company possesses advanced microsphere synthesis technology, surface modification techniques, and functional modification capabilities, which are critical for producing high-quality chromatography media [18][19]. - The company has established a comprehensive product range, including over 100 types of chromatography media and more than 1,000 specifications of analytical columns, catering to various applications in biopharmaceuticals [20][21]. Industry Risks - The company faces risks from policy changes in the pharmaceutical industry, which could slow down growth and affect demand for its chromatography products [9][10]. - Increased competition from both domestic and international players in the chromatography market poses a threat to the company's market share [14][13]. Quality Management - The company has obtained ISO 9001:2015 certification and adheres to GMP guidelines for quality management, ensuring high product quality and consistency [23]. Research and Development - The company invested 2.39 million yuan in R&D in the first half of 2025, representing 13.09% of its revenue, with a focus on enhancing its product offerings and technological capabilities [24].